Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma, T-Cell, Peripheral 15Lymphoma 14Lymphoma, T-Cell, Cutaneous 12Lymphoma, T-Cell 12Lymphoma, Large B-Cell, Diffuse 6Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Large-Cell, Anaplastic 5Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Leukemia 4Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Neoplasms 3Mycosis Fungoides 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lung Neoplasms 3Hodgkin Disease 3Hematologic Neoplasms 3Congenital Abnormalities 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sezary Syndrome 2

Interventions

Carboplatin 23Paclitaxel 18Bevacizumab 16Radiotherapy 15Erlotinib Hydrochloride 13Cisplatin 9Gemcitabine 7Gefitinib 7Docetaxel 7Taxes 6Pemetrexed 6Cetuximab 4Etoposide 3Amplified Fragment Length Polymorphism Analysis 3pegfilgrastim 2Vinorelbine 2Topotecan 2Radiotherapy, Conformal 2Radiation 2Irinotecan 2Gene Expression Profiling 2Anterior Temporal Lobectomy 2vandetanib 1sargramostim 1romidepsin 1lentiviral minigene vaccine of COVID-19 coronavirus 1irofulven 1cositecan 1advexin 1Video-Assisted Surgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma, Bronchiolo-Alveolar × romidepsin × Clear all
NCT01302808 2021-01-20

Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

University of Texas Southwestern Medical Center

Phase 1 Completed
17 enrolled 12 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡